Another study reported the activation of EGFR-dependent Notch3 signalling after erlotinib treatment of lung cancer cell lines with EGFR mutations, which is responsible for the enrichment of stem cell-like cancer cells 12. The gene discussed is EGFR; the disease is lung carcinoma.